Affiliation:
1. Department of Nuclear Medicine, University Hospital Würzburg, 97080 Würzburg, Germany
2. Bundeswehr Institute of Radiobiology Affiliated to the University of Ulm, 80937 Munich, Germany
Abstract
The combination of high and low LET radionuclides has been tested in several patient studies to improve treatment response. Radionuclide mixtures can also be released in nuclear power plant accidents or nuclear bomb deployment. This study investigated the DNA damage response and DNA double-strand break (DSB) repair in peripheral blood mononuclear cells (PBMCs) after internal exposure of blood samples of 10 healthy volunteers to either no radiation (baseline) or different radionuclide mixtures of the α- and β-emitters [223Ra]RaCl2 and [177Lu]LuCl3, i.e., 25 mGy/75 mGy, 50 mGy/50 mGy and 75 mGy/25 mGy, respectively. DSB foci and γ-H2AX α-track enumeration directly after 1 h of exposure or after 4 h or 24 h of repair revealed that radiation-induced foci (RIF) and α-track induction in 100 cells was similar for mixed α/β and pure internal α- or β-irradiation, as were the repair rates for all radiation qualities. In contrast, the fraction of unrepaired RIF (Qβ) in PBMCs after mixed α/β-irradiation (50% 223Ra & 50% 177Lu: Qβ = 0.23 ± 0.10) was significantly elevated relative to pure β-irradiation (50 mGy: Qβ, pure = 0.06 ± 0.02), with a similar trend being noted for all mixtures. This α-dose-dependent increase in persistent foci likely relates to the formation of complex DNA damage that remains difficult to repair.
Funder
Bundeswehr Medical Service
Reference60 articles.
1. Alpha and Beta Radiation for Theragnostics;Song;PET Clin.,2024
2. Global comparison of targeted alpha vs targeted beta therapy for cancer: In vitro, in vivo and clinical trials;Marcu;Crit. Rev. Oncol./Hematol.,2018
3. Alpha emitter radium-223 and survival in metastatic prostate cancer;Parker;N. Engl. J. Med.,2013
4. Drugmakers go nuclear, continuing push into radiopharmaceuticals;Dolgin;Nat. Biotechnol.,2021
5. Albertsson, P., Bäck, T., Bergmark, K., Hallqvist, A., Johansson, M., Aneheim, E., Lindegren, S., Timperanza, C., Smerud, K., and Palm, S. (2022). Astatine-211 based radionuclide therapy: Current clinical trial landscape. Front. Med., 9.